“We are excited to welcome the OÖ HightechFonds as an investor and see great value added in this cooperation,” says Jama Nateqi, CEO and cofounder of Symptoma. “With the investment, we will be able to drive forward our global growth in a 20 billion Euro market, while also focusing on further developing our technology and the database.”
Searching for symptoms
Symptoma is a search engine for diseases assisting physicians at assessing a patient’s medical condition with over 20.000 diagnoses linked to symptoms, risk factors, and statistics. Doctors can adjust the search by additionally entering the patient’s personal information, such as age and sex, so as to receive a more accurate result. A list of matching differential diagnoses, weighted by the probability regarding the specific case, can then help the physician determine a patient’s medical condition.
7 years, 7-digit investment
Initiated in 2007 as part of the AplusB Centre (BCCS) and officially founded in Austria in 2009 by Jama Nateqi and Thomas Lutz, the startup has been securing monthly profits in the mid five-digit euros range. The founding team spent seven years conducting research, gathering data and developing the tool. “The perfect search engine for diseases records and processes absolutely all medical information – that’s Symptoma’s goal,” says Thomas Lutz, Co-CEO and cofounder of Symptoma.
HighTech for medtech
„We are impressed with the performance of the company and the team behind it. They managed to make profits from the very beginning on, vastly exceeding the target figures,” says Horst Gaisbauer, from tech2b and Investment Manager at OÖ HightechFonds, an important player in the Upper Austrian tech scene. With a portfolio of about 16 million euros, OÖ HightechFonds seeks investments in tech startups with great medium- and long-term performance and yield potential. As a medtech startup with five-digit monthly profits, it is not surprising that Symptoma ranked high on the list for OÖ HighTechFonds. It is their seventh investment so far.
„Symptoma should become the standard in medicine for clarifying medical conditions,” says Friedrich Filzmoser of OÖ HightechFonds. Given their recent track record, they might well be on their way to conquering the medical market.
This story is brought to you in partnership with AplusB, a programme funded by FFG.